COR2ED

Real-world outcomes of elacestrant in ER+/HER2− ESR1-mutant metastatic breast cancer >> Findings from the Komodo–Foundation Medicine real-world analysis In this publication snapshot, Dr Seth Wander explores whether the benefits of elacestrant observed in the EMERALD trial are translating into clinical practice, drawing on findings from the Komodo–Foundation Medicine real-world analysis Key topics include: - The evolving ER+/HER2− mBC treatment landscape and the impact of ESR1 mutations - Key findings from the pivotal EMERALD trial - Real-world outcomes with elacestrant from the Komodo–Foundation Medicine analysis and how they complement existing evidence Watch Dr Wander’s video in this post 📺 Get the key clinical takeaways and view/download the infographic on our website: https://lnkd.in/egdv8sVc This programme is sponsored by Menarini Stemline and is intended for HCPs only. Brought to you by COR2ED Medical Affairs #MedicalEducation #Oncology

📣 Upcoming interactive webinar for HCPs only. Registrations open! “ATTR-CM: Where Clinical Insight Meets Patient Reality” For HCPs only. Developed & funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. This webinar focuses on disease awareness & diagnosis; treatments and specific medicinal products will not be discussed. Hosted by cardiologist Dr Philippe Debonnaire (Sint-Jan Hospital, Bruges, Belgium) and ATTR-CM patient advocate Mr Keith Dares (Canada) 🗓️ Monday 19th October ⏰ 14:00 CEST 📍 Online ➡️ Register now to save your place! https://lnkd.in/eYUaWy6r Conversation topics: · Recognising the red flags that may indicate ATTR-CM · Practical approaches and diagnostic tools to support accurate and timely diagnosis · Identifying barriers to diagnosis · What HCPs can learn from patient experiences · Q&A: Your chance to ask the speakers your pressing questions 📜 #medicaleducation TTR-INTX-00257 September 2026

📣 Upcoming interactive webinar for HCPs only. Registrations open! “ATTR-CM: Where Clinical Insight Meets Patient Reality” For HCPs only. Developed & funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. This webinar focuses on disease awareness & diagnosis; treatments and specific medicinal products will not be discussed. Hosted by cardiologist Dr Philippe Debonnaire (Sint-Jan Hospital, Bruges, Belgium) and ATTR-CM patient advocate Mr Keith Dares (Canada) 🗓️ Monday 19th October ⏰ 14:00 CEST 📍 Online ➡️ Register now to save your place! https://lnkd.in/eYUaWy6r Conversation topics: · Recognising the red flags that may indicate ATTR-CM · Practical approaches and diagnostic tools to support accurate and timely diagnosis · Identifying barriers to diagnosis · What HCPs can learn from patient experiences · Q&A: Your chance to ask the speakers your pressing questions 📜 #medicaleducation TTR-INTX-00257 September 2026

Heart attack warning signs everyone should know Heart attacks don’t always look and feel the same ️ ⚡️Recognising the early signs of a heart attack can save a life - immediate action is critical 📺 Watch the video to hear a patient testimony and learn about: - The signs of a first and second heart attack - Common and less common symptoms - How the feeling of a heart attack can differ, especially for women, older adults & people with diabetes or kidney disease - Why immediate action is critical - How recovery is physical AND emotional This video was developed with cardiologists Prof. Gilles Montalescot & Prof. Marco Valgimigli (Valgimigli Marco) View/download the accompanying infographic for quick reference: https://lnkd.in/eMhAkZ2e Endorsed by Fondazione Ticino Cuore and Parole & Réaction This educational programme is supported by an Independent Educational Grant from Viatris

Highlights from a satellite symposium at #ESCCongress 2026 from Prof. Giuseppe Patti ‘From acute ACS to early lipid intervention: Lessons from ARMYDA and beyond’ Watch for expert insights on: - Learnings from FAST-MI & ARMYDA-CATCH regarding the “strike early and strong” approach to treating ACS - Benefits of early PCSK9i use within 24h of an ACS event - How upstream evolocumab prior to PCI can improve clinical outcomes 📺 Prof. Patti’s update video in this post Watch more expert highlights from the symposium: https://lnkd.in/ddyRJZ2s Brought to you by COR2ED Medical Affairs in collaboration with Amgen #MedicalEducation #cardiology

Expert insights on LDL-C management in coronary artery disease Highlights from a satellite symposium at #ESCCongress 2026 Prof. Ulrich Laufs explains how: - Advanced plaque imaging is essential to identify dangerous lipid-rich plaques that can be modified through intensive therapy - VESALIUS-CV shows that lowering LDL-C to v. low levels w/ evolocumab reduces mortality in high-risk pts even before a first major CV event - Visually showing plaque to pts significantly improves medication adherence + streamlines pt communication 📺 Prof. Laufs' update in this post Get more expert insights from the symposium: https://lnkd.in/dxgfmVpk Brought to you by COR2ED Medical Affairs in collaboration with Amgen #MedicalEducation #cardiology